Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

Yale University

Status and phase: Completed; Phase 2

Conditions: Schizophrenia; Schizoaffective Disorder

Treatments: Drug: Cannabidiol; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00588731

07TGS-1082

0710003164

Details and patient eligibility

About

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.

Enrollment: 41 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

Exclusion criteria

• Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

41 participants in 2 patient groups, including a placebo group

Cannabidiol

Experimental group

Treatment:

Drug: Cannabidiol

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo